New training aims to ease burden on caregivers of schizophrenia patients
NCT ID NCT05036590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether training mental health professionals to deliver a short psychoeducational program (BREF) can reduce the burden on caregivers of people with schizophrenia or first psychotic episode. The trial will include 206 caregivers, comparing those who receive the program to those who do not. The goal is to see if this training helps caregivers feel less stressed and better able to cope.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- psychoeducational program (BREF)
- What this could lead to
- If successful, this could provide a practical way to train professionals to support caregivers, reducing their stress and improving patient outcomes.
- What could go wrong
- This is a non-randomized study with a control period, so results may be influenced by other factors. The program's effectiveness depends on implementation quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 206 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * people over 18yo * first-degree relatives (parents, siblings, children) or spouse of the patient * primary caregiver of a patient with schizophrenic disorders or first psychotic episode (DSM5) * consenting to participate to the study Exclusion Criteria: * mental disorder on Axis I * having already benefited from a family intervention such as psychoeducation * caring for several people with severe psychiatric disorders * receiving income for the caring activities * being legally responsible of the patient * having difficulty understanding fluent French * illiterate
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hopital Vinatier
RECRUITINGBron, 69678, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia